Other
Recurrence
0
Pipeline Programs↗
14
Active Trials↗
2
Companies Involved↗
Recurrence is an early-stage landscape with 0 programs across 2 companies. The most active players are Merck & Co., Endo Pharmaceuticals.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
41
clinical trials
Completed16 · 39%
Recruiting10 · 24%
Unknown status8 · 20%
Not yet recruiting4 · 10%
Terminated2 · 5%
Withdrawn1 · 2%
Clinical Trials
Trial Activity
41 trials
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Recruiting·—·Phase 2·NCT04434040·40 enrolled
RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal Dissection
Recruiting·—·N/A·NCT03183115·100 enrolled
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
Not yet recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT05778097·103 enrolled
Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option
Not yet recruiting·—·Phase 2·NCT07032649·100 enrolled
Evidence-Based Evaluation of Classic Herb Pair (Chuanxiong Rhizoma and Salviae Miltiorrhizae) for Preventing Recurrence of Diabetic Lower Extremity Arterial Disease
Not yet recruiting·—·Phase 1·NCT07139639·350 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)